Genocure, Cooperates with OliPass... Targeting the Regenerative Medicine Bio Market

Genocure and OliPass sign a business agreement for joint work

PDRN-related biotechnology research, development, and commercialization cooperation planned

2024-12-10 (Tue)

Gecocure CEO, Oh Bo Gyeong (left) and OliPass CEO, Lee Jin Han are taking a photo after signing the 'Business Agreement

for PDRN-related bio research and development, technology sharing and joint work' at OliPass headquarters on the 10th.

Genocure Co., Ltd., a company specializing in regenerative medical biomaterials, is partnering with OliPass, listed on the KOSDAQ, to enter the global regenerative medical bio market.

Genocure announced on the 10th that it is signed a business agreement with OliPass for 'PDRN-related bioresearch and development, technology sharing and joint work' at OliPass's headquaters.

The agreement aims to provide a foundation for the two companies to enter the global market through the development of advanced biomaterials and technological advancement based on PDRN and PN, eventually strengthening domestic and international distribution and sales. Two companies are planning to maximize the performance of their business by cooperating in the production of PDRN raw materials and mutually supporting professional manpower and resources.

OliPass will strengthen the expertise of the newly established business division through this agreement. Genocure plans to expand its position in the next generation biomaterials market based on its recombinant PDRN technology. It is expected to become a game-changer in the field of regenerative medicine thorugh the mass production of PDRN and the expansion of its global distribution network.

Through this agreement, both companies will establish the central position as the domestic bioresearch and development and present innovation to the domestic and international regenerative medical bio market.

On November 22, Genocure succeeded in developing the world's very first 'recombinant PDRN', a next generation PDRN production technology that can produce PDRN with high purity. It signed a CDMO-MSA contract with Asymchem, a global CDMO company in China, to advance 'recombinant PDRN', GMP process development, and mass production.

Regarding this agreement, Oh Bo Gyeong, CEO of Genocure, said, "This agreement is an opportunity to reaffirm Genocure's status as a leading company with the technology that can infinitely produce mass PDRN without raw materials. Through this strategic cooperation with OliPass, we will achieve a greater leap forward in regenerative medicine and bio fields." 

Lee Jin Han, CEO of OliPass, said, "OliPass will expand technological capabilities and strengthen its competitiveness in the global bio market through this joint business with Genocure."

[CEO ScoreDaily / Reporter Kim Yoon Sun / yskk@ceoscore.co.kr]